GlassScriptPhysician profile
Zahid Akram
NPI 1821071457
$67,675.22
in general payments reported to CMS, 2019-2025
54 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,241 · 2020: $7,557 · 2021: $10K · 2022: $5,756 · 2023: $11K · 2024: $15K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $13K · Travel and Lodging: $2.68 · Education: $0.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,510.32 |
| Food and Beverage | $13,491.82 |
| Travel and Lodging | $2.68 |
| Education | $0.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $43,031.06 | 2019-2025 | |
| Biogen, INC. | $2,468.03 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Ucb, INC. | $2,381.32 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $2,030.92 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $1,413.57 | 2019-2025 | |
| Genentech USA, INC. | $1,384.79 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Abbvie INC. | $1,133.57 | 2021-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $920.63 | 2019-2025 | Aimovig, Uplizna |
| Mdd US Operations, LLC | $878.08 | 2019-2025 | Gocovri, Gocovri |
| Celgene Corporation | $864.47 | 2019-2025 | Zeposia |
| Lilly USA, LLC | $859.56 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Acadia Pharmaceuticals INC | $847.31 | 2019-2025 | Nuplazid, Daybue |
| Emd Serono, INC. | $818.91 | 2019-2025 | |
| Argenx US, INC. | $688.39 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $612.38 | 2020-2024 | Xcopri |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zahid Akram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.